Gilead passes on fully acquiring Pionyr, as eyes now turn to Tizona, a fellow summer 2020 buyout option

Gilead and Pionyr Immunotherapeutics, a biotech trying to follow up on the first generation of checkpoint inhibitors, have “mutually agreed” on a rewrite to their 2020 terms, with Gilead deciding not to buy out the company. The California biopharma waived its option to acquire the remaining 50.1% of Pionyr, which…